Mechanism of Action

  1. Rachmilewitz J, Gileadi O, Eldar-Geva T, Schneider T, de Groot N, Hochberg A. Transcription of the H19 gene in differentiating cytotrophoblasts from Human placenta . Mol. Rep and Dev (1992)
  2. Matouk I, Ohana P, Ayesh S, Sidi A, Czerniak A, de Groot N, Hochberg A. The oncofetal H19 RNA in human cancer from the bench to the patient. Cancer Therapy (2005).
  3. Matouk I, de Groot N, Mezan S, Ayesh S, Abu-lail R, ochberg A, Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE (2007).
  4. Matouk I, Mezan S, Mizrahi A, Ohana P, Abu-lail R, Fellig Y, de Groot N, Galun E, Hochberg A. The oncofetal H19 RNA connection: Hypoxia, p53 and cancer. Biochimia et Biophysica Acta (2010)
  5. Ohana P, *Matouk I, Amit D, Gilon M, Hochberg A. Toxin Based Cancer Gene Therapy – Under the Control of Oncofetal H19 Regulatory Sequences. In the book: Gene Therapy of Cancer, Third Edition. Academic press (2013).
  6. Matouk I, Raveh E, Ohana P, Abu-lail R, Gershtain E, Gilon M, Hochberg A. The increasing complexity of the oncofetal H19 gene locus: Functional dissection and therapeutic intervention. International Journal of Molecular Sciences (2013).
  7. Matouk IJ , Raveh E, Abu-Lail R, Mezan S, Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M, Richler C, Fellig Y, Sorin V, Hubert A, Hochberg A, Czerniak A. Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys Acta (2014)

Bladder

  1. Ohana P, Kopf E, Bibi O, Ayesh S, Schneider T, Laster M, Tykocinski M, de Groot N, Hochberg A.  The expression of the H19 gene and its function in human bladder carcinoma cell lines. FEBS Letters (1999)
  2. Ariel I, Sughayer M, Felig Y, Pizov G, Ayesh S, Podeh D, Abu-Libdeh B, Levy C, Birman T, Tykocinski M.L., de Groot N, Hochberg A. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. J. Clin. Path.: Mol. Path (2000)
  3. Ariel I, Ayesh S, Gofrit O, Ayesh B, Abdul-Ghani R, Pisov G, Smith Y, Sidi A, Birman T, Schneider T, de Groot N, Hochberg A. Gene expression in bladder carcinoma rat model. Mol. Carcinogenesis (2004)
  4. Ohana P, Gofrit O, Ayesh S, Al-Sharef W, Mizrahi A, Birman T, Schneider T, Matouk I, de Groot N, Tavdy E, Sidi A and Hochberg A. Regulatory sequences of H19 gene in DNA based therapy of bladder cancer. Gene Therapy and Molecular Biology. (2004)
  5. Gofrit O, Birman T, Dinaburg A, Ayesh S, Ohana P, Hochberg A. Chemically induced bladder cancer- a sonographic and morphologic description. Urology (2006)
  6. Sidi A, Ohana P, Benjamin S, Shalev M, Ransom J.H., Lamm D, Hochberg A, Leibovitch I. Phase I/II Marker Lesion Study of Intravesical BC-819 DNA Plasmid in H19 Overexpressing Superficial Bladder Cancer Refractory to Bacillus Calmette Guerin. J. Urology (2008)
  7. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res (2009)
  8. Matouk I, Evantal N, Amit D, Ohana P, Gofrit O, Sorin V, Birman T, Gershtain E, Hochberg A. The H19-IGF2 Role in Bladder Cancer Biology and DNA-Based Therapy. Bladder Cancer – From Basic Science to Robotic Surgery (2012)
  9. Gofrit ON, Benjamin S, Halachmi S, Leibovitch I, Dotan Z, Lamm DL, Ehrlich N, Yutkin V, Ben-Am M, Hochberg A. DNA Based Therapy with Diphtheria Toxin-A BC-819: A Phase 2b Marker Lesion Trial in Patients with Intermediate Risk Nonmuscle Invasive Bladder Cancer. J Urol (2013)